Barrow, Hanley, Mewhinney & Strauss’s Integra LifeSciences IART Stock Holding History

Barrow, Hanley, Mewhinney & Strauss’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.59K	Hold	275	–	–	﹤0.01%	317
2025 Q4	$3.42K	Hold	275	–	–	﹤0.01%	290
2025 Q3	$3.94K	Hold	275	–	–	﹤0.01%	290
2025 Q2	$3.37K	Hold	275	–	–	﹤0.01%	276
2025 Q1	$6.05K	Hold	275	–	–	﹤0.01%	245
2024 Q4	$6.24K	Hold	275	–	–	﹤0.01%	256
2024 Q3	$5K	Buy	+275	New	+$6.37K	﹤0.01%	267

Other funds holding IART

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss's IART Position: Q1 2026 in Review

Barrow, Hanley, Mewhinney & Strauss held its Integra LifeSciences (IART) position steady in Q1 2026 at 275 shares worth $2.59K. The position accounts for ﹤0.01% of the portfolio, ranked #317.

Barrow, Hanley, Mewhinney & Strauss first reported a position in IART in Q3 2024 and has held it in 7 quarters since. The position peaked at $6.24K in Q4 2024. 201 funds tracked by Wall St. Rank hold IART as of Q1 2026.

Barrow, Hanley, Mewhinney & Strauss held 275 shares of Integra LifeSciences worth $2.59K as of Q1 2026.
Barrow, Hanley, Mewhinney & Strauss left its Integra LifeSciences share count unchanged in Q1 2026.
Integra LifeSciences made up ﹤0.01% of Barrow, Hanley, Mewhinney & Strauss's portfolio in Q1 2026, its #317 holding.
Barrow, Hanley, Mewhinney & Strauss first reported a position in Integra LifeSciences in Q3 2024 and has held it in 7 quarters since.
Barrow, Hanley, Mewhinney & Strauss's Integra LifeSciences position peaked at $6.24K in Q4 2024.
201 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2026.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q1 2026, filed 13 May 2026.